curriculum vitae luiz belardinelli, m.d.training.cvrc.virginia.edu/events/474resume.pdf · ed. may...

Ed. May 16, 2014

1

CURRICULUM VITAE

Luiz Belardinelli, M.D. Address Gilead Sciences, Inc. Telephone (650) 524-3889 333 Lakeside Drive Fax (650) 522-1654 Foster City, CA 94404 Email [email protected] Experience: 1975 - MD degree from Catholic University, School of Medicine Porto Alegre, Brazil 1976 - 1977 Post-Doctorate, University of Virginia, Department of Physiology, Charlottesville, Virginia 1977 - 1979 Research Associate, University of Virginia, Department of Physiology, Charlottesville, Virginia 1980 - 1983 Research Assistant Professor, University of Virginia, Departments of Medicine and Physiology, Charlottesville, Virginia 1980 - 1985 Assistant Professor, University of Virginia, Departments of Medicine and Physiology (Joint Appointment), Charlottesville, Virginia 1985 - 1988 Associate Professor, University of Virginia, Departments of Medicine and Physiology (Joint Appointment), Charlottesville, Virginia 1988 - 1999 Professor of Medicine and Pharmacology, Eminent Scholar,

University of Florida, Departments of Medicine and Pharmacology (Joint Appointment), Gainesville, Florida

1999 - 2000 Director of Pharmacology, CV Therapeutics, Inc. Palo Alto, California 2000 - 2004 Vice President, Drug Research and Pharmacological Sciences, CV Therapeutics, Inc.

Palo Alto, California

2004 - 2008 Senior Vice President, Pharmacology and Translational Biomedical Research, CV Therapeutics, Inc. Palo Alto, California 2008 - 2009 Senior Vice President, Clinical Research and Pharmacology, CV Therapeutics, Inc. Palo Alto, California 2009 - Present Senior Vice President, Cardiovascular Therapeutics, Gilead Sciences Fremont, Inc. California Professional Honors and Awards

Young Investigator Award - Eleventh Interamerican Congress of Cardiology, Puerto Rico, September, 1980

NIH Research Career Development Award 12/1981 - 12/1986 Dr. Harold Lamport Award of the American Physiology Society Cardiovascular Section

1984

Luiz Belardinelli, M.D.

2

Eminent Scholar Chair in Cardiovascular Research, American Heart Association, appointed January 1, 1988 Inventor of the Year Award, Alumni Association of the University of Virginia, April, 1992 Clinical Investigator Award, American Society for Clinical Investigation

Editorial Board, British Journal of Pharmacology -- elected January 1, 1996 to 4 year appointment University of Florida Research Foundation Professorship, July 1, 1997 - June 30, 2001 CVT Distinguished Fellow of Cardiovascular Science, 2002

Research Grants NIH Research Awards from 1983 to 2001 American Heart Association Grant-in-Aids and Fellowships (National and Affiliate) from 1981 to 1999 Professional Memberships American Association for the Advancement of Science (1980) American Federation for Clinical Research (1980) American Heart Association American Physiological Society, Cardiovascular Section American Society for Clinical Investigation British Pharmacological Society Cardiac Electrophysiology Society Heart Rhythm Society The International Society for Computerized Electrophysiology Patents 1. Adenosine in the treatment of supraventricular tachycardia. (Patent No. 4,673,563) Licensed

(Adenocard, USA; Adenocor, UK) 2. U.S. Patent Serial No. 08/330,640. "Xanthine Epoxides as A1 Adenosine Receptor Agonists and

Antagonists" UF #1324 3. U.S. Patent Serial No. 08/470,113 [C.P.I.] "Novel A1 Adenosine Receptor Agonists and

Antagonists" UF #1439 4. N.B. Licensing agreement for patent "Novel A1 adenosine receptor agonists and antagonists" with

C.V. Therapeutics, California. 5. Metabolic catheter (double lumen catheter for measurement of plasma levels of adenosine) (Patent

No. 5,009,634) 6. Use of adenosine, adenosine analogs or nucleoside uptake blockers as drug treatment for

obstructive sleep apnea. (Patent No. 5,075,290) 7. Several other patents since joining CV Therapeutics. (Approximately 125 patents and 150 patent applications. Specific patent titles, patent numbers, and dates available upon request.)


3

BIBLIOGRAPHY I. Refereed Publications

– Published and in press Papers, approximately: 287 1. Harder D, Belardinelli L, Sperelakis N, Rubio R, Berne RM. Differential effects of adenosine and

nitroglycerin on the action potentials of large and small coronary arteries. Circ Res 44:176-182, 1979.

2. Belardinelli L, Harder D, Sperelakis N, Rubio R, Berne RM. Cardiac glycoside stimulation of inward

calcium current in vascular smooth muscle of canine coronary artery. J Pharm Exp Ther 209:62-66, 1979.

3. Belardinelli L, Rubio R, Berne RM. Blockade of Ca++ dependent rat atrial slow action potentials by

adenosine and lanthanum. Pflgers Arch 380:19-27, 1979. 4. Belardinelli L, Vogel S, Sperelakis N, Rubio R, Berne RM. Restoration of slow responses in hypoxic

heart muscle by alkaline pH. J Mol Cell Cardiol 11:877-892, 1979. 5. Miller WL, Belardinelli L, Bacchus A, Foley D, Rubio R, Berne RM. Canine myocardial adenosine

and lactate production, oxygen consumption, and coronary blood flow during stellate ganglia stimulation. Circ Res 45:708-718, 1979.

6. Tominaga S, Curnish R, Belardinelli L, Rubio R, Nakamura T, Berne R M. Adenosine release during

early and sustained exercise of canine skeletal muscle. Am J Physiol 238:H156-H163, 1980. 7. Pelleg A, Vogel S, Belardinelli L, Sperelakis N. Overdrive suppression of automaticity in cultured

chick myocardial cells. Am J Physiol 238:H24-H30, 1980. 8. Harder RD, Belardinelli L. Effects of propafenone on TEA-induced action potentials in vascular

smooth muscle of canine coronary arteries. Experientia 36:1082-1083, 1980. 9. Belardinelli L, Belloni FL, Rubio R, Berne RM. Atrioventricular conduction disturbances during

hypoxia: Possible role of adenosine in rabbit and guinea pig heart. Circ Res 47:684-691, 1980. 10. Belardinelli L, Mattos EC, Berne RM. Evidence for adenosine mediation of atrioventricular block in

ischemic canine myocardium. J Clin Invest 68:195-205, 1981. 11. Belardinelli L, Vogel S, Linden J, Berne RM. Antiadrenergic action of adenosine on ventricular

myocardium in embryonic chick hearts. J Mol Cell Cardiol 14:291-294, 1982. 12. Belardinelli L, Fenton AR, West A, Linden J, Althaus JS, Berne RM. Extracellular action of

adenosine and the antagonism by aminophylline on the atrioventricular conduction of isolated perfused guinea pig and rat hearts. Circ Res 51:569-579, 1982.

13. Belardinelli L, Isenberg G. Isolated atrial myocytes: adenosine and acetylcholine increase

potassium conductance. Am J Physiol 224:H374-H737, 1983. 14. Belardinelli L, Isenberg G. Actions of adenosine and isoproterenol on isolated mammalian

ventricular myocytes. Circ Res 53:287-297, 1983. 15. DiMarco J, Sellers T, Berne RM, West GA, Belardinelli L. Adenosine: electrophysiologic effects and

therapeutic use for terminating paroxysmal supraventricular tachycardia. Circulation 68:1254-1263, 1983.


4

16. Berne RM, DiMarco JP, Belardinelli L. Dromotropic effects of adenosine and adenosine antagonists in the treatment of cardiac arrhythmias involving the atrioventricular node. Circulation 68:1195-1197, 1984.

17. DiMarco JP, Sellers TD, Belardinelli L. Paroxysmal supraventricular tachycardia with Wenckebach

block: evidence for reentry within the upper portion of the atrioventricular node. J Am Coll Cardiol 3:1551-1555, 1984.

18. Isenberg G, Belardinelli L. Ionic basis for the antagonism between adenosine and isoproterenol on

isolated mammalian ventricular myocytes. Circ Res 55:309-325, 1984. 19. Belardinelli L, Shryock J, West GA, Clemo HF, DiMarco JP, Berne RM. Effects of adenosine and

adenine nucleotides on the atrioventricular node of isolated guinea pig hearts. Circulation 70:1083-1091, 1984.

20. Berne RM, Belardinelli L. Effects of hypoxia and ischemia on coronary vascular resistance, A-V

node conduction and S-A node excitation. Acta Med Scan (Suppl) 694:9-19, 1984. 21. West GA, Belardinelli L. Correlation of sinus slowing and hyperpolarization caused by adenosine in

sinus node. Pflgers Arch 403:75-81, 1985. 22. West GA, Belardinelli L. Sinus slowing and pacemaker shift caused by adenosine in rabbit SA node.

Pflgers Arch 403:66-74, 1985. 23. Favale S, DiBiase M, Rizzo U, Belardinelli L, Rizzon P. Effect of adenosine and adenosine-5'-

triphosphate on atrioventricular conduction in patients. J Am Coll Cardiol 5:1212-1219, 1985. 24. DiMarco JP, Sellers TD, Lerman BB, Greenberg ML, Berne RM, Belardinelli L.: Diagnostic and

therapeutic use of adenosine in patients with supraventricular tachyarrhythmias. J Am Coll Cardiol 6:417-425, 1985.

25. Wesley RC, Belardinelli L. Role of adenosine on ventricular overdrive suppression in isolated

guinea pig hearts and Purkinje fibers. Circ Res 57:517-531, 1985. 26. West GA, Isenberg G, Belardinelli L. Antagonism of forskolin effects by adenosine in isolated hearts

and ventricular myocytes. Am J Physiol 250:H769-H777, 1986. 27. Lerman BB, Belardinelli L, West GA, Berne RM, DiMarco JP. Adenosine-sensitive ventricular

tachycardia: evidence suggesting cyclic AMP-mediated triggered activity. Circulation 74:270-280, 1986.

28. Wesley RC, Lerman BB, DiMarco JP, Berne RM, Belardinelli L. Mechanism of atropine-resistant

atrioventricular block during inferior myocardial infarction: possible role of adenosine. J Am Coll Cardiol 8:1232-1234, 1986.

29. Clemo HF, Belardinelli L. Effect of adenosine on atrioventricular conduction. I: Site and

characterization of adenosine action in the guinea pig atrioventricular node. Circ Res 59:427-436, 1986.

30. Clemo HF, Belardinelli L. Effect of adenosine on atrioventricular conduction. II: Modulation of

atrioventricular node transmission by adenosine in hypoxic isolated guinea pig hearts. Circ Res 59:437-446, 1986.

31. Wesley RC, Boykin MT, Belardinelli L. Role of adenosine as mediator of bradyarrhythmias during

hypoxia in isolated guinea pig hearts. Cardiovasc Res 20, 752-759, 1986. 32. Clemo HF, Bourassa A, Linden A, Belardinelli L. Antagonism of the effects of adenosine and

hypoxia on atrioventricular conduction time by two novel alkylxanthines: correlation with binding to adenosine A1 receptors. J Pharmacol Exp Ther 242:478-484, 1987.


5

33. Jenkins JR, Clemo HF, Belardinelli L. A microcomputer system for on-line study of atrioventricular

node accommodation. PACE 10:1301-1308, 1987. 34. Findley LJ, Boykin M, Fallon T, Belardinelli L. Plasma adenosine and hypoxemia in patients with

sleep apnea. J Appl Physiol, 64:556-561, 1988. 35. Jenkins JR, Belardinelli L. Atrioventricular nodal accommodation in isolated guinea pig hearts:

physiological significance and role of adenosine. Circ Res, 63:97-116, 1988. 36. Belardinelli L, Giles WR, West A. Ionic mechanisms of adenosine actions in pacemaker cells from

rabbit heart. J Physiol (Lond) 405:615-633, 1988. 37. Lerman BB, Wesley RC, DiMarco JP, Haines DE, Belardinelli L. Antiadrenergic effects of adenosine

on His-Purkinje automaticity. J Clin Invest 82:2127-2135, 1988. 38. Shryock J, Patel A, Belardinelli L, Linden J. Down regulation and desensitization of A1-adenosine

receptors in embryonic chicken heart. Am J Physiol 256:H321-H327, 1989. 39. Belloni FL, Belardinelli L, Halperin C, Hintze TH. An unusual receptor mediates adenosine-induced

SA nodal bradycardia in dogs. Am J Physiol 256:H1553-H1564, 1989. 40. Wesley RC, Belardinelli L. Role of endogenous adenosine in postdefibrillation bradyarrhythmia and

hemodynamic depression. Circulation 80:128-137, 1989. 41. Belardinelli L, Linden J, Berne RM. The cardiac effects of adenosine. Prog Cardiovasc Dis 32:73-

97, 1989. 42. Wu S-N, Linden J, Visentin S, Boykin M, Belardinelli L. Enhanced sensitivity of heart cells to

adenosine and up-regulation of receptor number after treatment of guinea pigs with theophylline. Circ Res 65:1066-1077, 1989.

43. Lerman BB, Wesley RC, Belardinelli L. Electrophysiologic effects of dipyridamole on atrioventricular

nodal conduction and supraventricular tachycardia. Circulation 80:1536-1543, 1989. 44. Belardinelli L, Lerman BB. Electrophysiological basis for the use of adenosine in the diagnosis and

treatment of cardiac arrhythmias. Br Heart J 63:3-4, 1990. 45. Visentin S, Wu S-N, Belardinelli L. Adenosine-induced changes in atrial action potential: contribution

of Ca and K currents. Am J Physiol 258:H1070-H1078, 1990. 46. Shryock JC, Boykin MT, Hill JA, Belardinelli L. A new method of sampling blood for measurement of

plasma adenosine. Am J Physiol 258:H1232-H1239, 1990. 47. Belardinelli L, Pelleg A. Cardiac electrophysiology and pharmacology of adenosine. J Cardiovasc

Electrophysiol 1:327-339,1990. 48. Froldi L, Belardinelli L. Species-dependent effects of adenosine on heart rate and atrioventricular

nodal conduction. Mechanism and physiological implications. Circ Res 67:960-978, 1990. 49. Tietjan CS, Tribble CG, Gidday JM, Phillips CL, Belardinelli L, Rubio R, Berne RM. Interstitial

adenosine in guinea pig hearts: an index obtained by epicardial disks. Am J Physiol 259:H1471-H1476, 1990.

50. Granato JE, Watson DD, Belardinelli L, Cannon JM, Beller GA. Effects of dipyridamole and

aminophylline on hemodynamics, regional myocardial blood flow and thallium-201 washout in the setting of a critical coronary stenosis. J Am Col Cardiol 16:1760-1770, 1990.


6

51. Ragazzi E, Wu S-N, Shryock J, Belardinelli L. Electrophysiological and receptor binding studies to assess activation of the cardiac adenosine receptor by adenine nucleotides. Circ Res 68:1035-1044, 1991.

52. Lerman BB, Belardinelli L. Cardiac electrophysiology of adenosine. Basic and Clinical Concepts.

Circulation 83:1499-1509, 1991. 53. Belardinelli L, Lerman BB. Adenosine: Cardiac Electrophysiology. PACE 14:1672-1680, 1991. 54. Dennis D, Jacobson K, Belardinelli L. Evidence of spare A1-adenosine in guinea pig atrioventricular

node. Am J Physiol 262:H661-H671, 1992. 55. Shryock JC, Travagli HC, Belardinelli L. Evaluation of N-0861, (ñ)-N6-Endonorbornan-2-yl-9-

methyladenine, as an A1 subtype-selective adenosine receptor antagonist in the guinea pig isolated heart. J Pharmacol Exp Ther 260:1292-1299, 1992.

56. Song Y, Thedford S, Lerman BB, Belardinelli L. Adenosine-sensitive after depolarizations and

triggered activity in guinea pig ventricular myocytes. Circ Res 70:743-753, 1992. 57. Belardinelli L, Shryock JC. Does adenosine function as a retaliatory metabolite in the heart? NIPS

7:52-56, 1992. 58. Keim S, Curtis AB, Belardinelli L, Epstein ML, Staples ED, Lerman BB. Adenosine-induced

atrioventricular block: a rapid and reliable method to assess surgical and radiofrequency catheter ablation of accessory atrioventricular pathways. J Am Coll Cardiol 19:1005-1012, 1992.

59. Hill JA, Utterback DB, Keim SG, Dugger D, Mayfield, WR, Shryock JC, Belardinelli L. A catheter-

syringe sampling system for measurement of adenosine in coronary sinus blood in humans. Coronary Artery Disease 3:963-971, 1992.

60. Shryock J, Song Y, Wang D, Baker SP, Olsson RA, Belardinelli L. Selective A2-adenosine receptor

agonists do not alter action potential duration, twitch shortening, or cAMP accumulation in guinea pig, rat, or rabbit isolated ventricular myocytes. Circ Res 72:194-205, 1993.

61. Pelleg A, Belardinelli L. Cardiac electrophysiology and pharmacology of adenosine: basic and

clinical aspects. Cardiovasc Res 27:54-61, 1993. 62. Belardinelli L. Adenosine system in the heart. Drug Dev. Res. 28:263-267, 1993. 63. Belardinelli L, Shryock JC, Pelleg A. Cardiac electrophysiologic properties of adenosine. Coronary

Artery Disease 3:1122-1126, 1992. 64. Beller GA, Granato JE, Cannon JM, Belardinelli L, Watson DD. Effects of intracoronary

dipyridamole infusion on regional myocardial blood flow and intrinsic thallium-201 washout in dogs with a critical coronary stenosis. Am Heart J 124:56-64, 1992.

65. Dennis DM, Shryock JC, Belardinelli L. Correlation of (-) N6-phenylisopropyladenosine blood levels

with cardiac responses in the anesthetized guinea pig. J Pharmacol Exp Ther 265:543-550, 1993. 66. Amoah-Apraku B, Lu J, Lu JY, Pelleg A, Bruns RF, Belardinelli L. Selective potentiation by an A1

adenosine receptor enhancer of the negative dromotropic action of adenosine in the guinea pig heart. J Pharmcol Exp Ther 266:611-617, 1993.

67. Bertolet BD, Belardinelli L, Hill JA. Absence of adenosine-induced chest pain after total cardiac

afferent denervation. Am J Cardiol 72:483-484, 1993. 68. Sidi A, Wesley R, Barrett R, Rush W, Belardinelli L. Cardiovascular effects of a non-xanthine-

selective antagonist of the A1 adenosine receptor in the anaesthetized pig: pharmacological and therapeutic implications. Cardiovasc Res 28:621-628, 1994.


7

69. Bertolet BD, Belardinelli L, Kerensky R, Hill JA. Adenosine blockade as primary therapy for

ischemia-induced accelerated idioventricular rhythm: rationale and potential clinical application. Am Heart J 128:185-188, 1994.

70. Utterback DB, Staples ED, White SE, Hill JA, Belardinelli L. Basis for the selective reduction of

pulmonary vascular resistance in humans during infusion of adenosine. J Appl Physiol 76:724-730, 1994.

71. Scammells PJ, Baker SP, Belardinelli L, Olsson RA. Substituted 1,3-dipropylxanthines as

irreversible antagonists of A1 adenosine receptors. J Med Chem 37:2704-2712, 1994. 72. Kabell G, Buchanan LV, Gibson JK, Belardinelli L. Effects of adenosine on atrial refractoriness and

arrhythmias. Cardiovasc Res 28:1385-1389, 1994. 73. Song Y, Belardinelli L. ATP promotes development of after depolarizations and triggered activity in

cardiac myocytes. Am J Physiol 267:H2005-H2011, 1994. 74. Kollias-Baker C, Ruble J, Dennis D, Bruns RF, Linden J, Belardinelli L. Allosteric enhancer PD

81,723 acts by novel mechanism to potentiate cardiac actions of adenosine. Circ Res 75:961-971, 1994.

75. Kollias-Baker C, Xu J, Pelleg A, Belardinelli L. Novel approach for enhancing atrioventricular nodal

conduction delay mediated by endogenous adenosine. Circ Res 75:972-980, 1994. 76. Belardinelli L, Lu J, Dennis D, Martens J, and Shryock JC. The cardiac effects of a novel A1-

adenosine receptor agonist in guinea pig isolated heart. J Pharmacol Exp Ther 271:1371-1382, 1994.

77. Wang D and Belardinelli L. Mechanism of the negative inotropic effect of adenosine in guinea pig

atrial myocytes. Am J Physiol 267:H2420-H2429, 1994. 78. Conti JB, Belardinelli L, Utterback DB, and Curtis AB. Endogenous adenosine is an antiarrhythmic

agent. Circulation 91:1761-1767, 1995. 79. Belardinelli L, Shryock JC, Song Y, Wang D, and Srinivas M. Ionic basis of the electrophysiological

actions of adenosine on cardiomyocytes. FASEB J 9:359-365-, 1995. 80. Dennis DM, Shryock JC, and Belardinelli L. Homologous desensitization of the A1-adenosine

receptor system in the guinea pig atrioventricular node. J Pharmacol Exp Ther 272:1024-1035, 1995.

81. Conti JB, Belardinelli L, and Curtis AB. Usefulness of adenosine in diagnosis of tachyarrhythmias.

Am J Cardiol 75:952-955, 1995. 82. Bertolet BD, McMurtie EB, Hill JA, Belardinelli L. Theophylline for the treatment of atrioventricular

block after myocardial infarction. Ann Intern Med 123:509-511, 1995. 83. Belardinelli L, Shryock JC, Zhang Y, Scammells PJ, Olsson R, Dennis D, Milner P, Pfister J, and

Baker SP.1,3-Dipropyl-8-[2-(5,6-Epoxy) Norbornyl]xanthine, a potent, specific and selective A1 adenosine receptor antagonist in the guinea pig heart and brain and in DDT1MF-2 cells. J Pharmacol Exp Ther 275:1167-1176, 1995.

84. Wang D, Shryock JC, and Belardinelli L. Cellular basis for the negative dromotropic effect of

adenosine on rabbit single atrioventricular cells. Circ Res 78:697-706, 1996. 85. Bertolet BD, Belardinelli L, Franco EA, Nichols WW, Kerenksy RA, and Hill JA. Selective attenuation

by N-0861 (N6-endonorboran-2-yl-9-methyladenine) of cardiac A1 adenosine receptor-mediated effects in humans. Circulation 93:1871-1876, 1996.


8

86. Scammels PJ, Baker SP, Belardinelli L, Olsson RA, Russell RA, and Wright DMJ. The synthesis of

the novel adenosine agonists, exo- and endo- N6-(5,6-epoxynorborn-2-yl)adenosine. Tetrahedron 52:4735-4744, 1996.

87. Srinivas M, Shryock JC, Scammells PJ, Ruble J, Baker SP, and Belardinelli L. A novel irreversible

antagonist of the A1-adenosine receptor. Molecular Pharmacology 50:196-205, 1996. 88. Scammels PJ, Baker SP, Belardinelli L, Olsson RA, Russell RA, and Knevitt SA. The design and

Synthesis of Novel Adenosine Agonists. Bioorg Med Chem Letts 6:811-814, 1996. 89. Bertolet BD, Eagle DA, Conti JB, Mills Jr. RM, Belardinelli L. Bradycardia After Heart

Transplantation: Reversal With Theophylline. J Am Coll Cardiol 28:396-399, 1996. 90. Song Y and Belardinelli L. Electrophysiological and functional effects of adenosine on ventricular

cardiomyocytes of various mammalian species. Am J Physiol. (Cell Physiol. 40): C1233-C1243, 1996.

91. Dennis DM, Raatikainen MJP, Martens JR, Belardinelli L. Modulation of atrioventricular nodal

function by metabolic and allosteric regulators of endogenous adenosine in guinea pig heart. Circulation 94:2551-2559, 1996.

92. Bertolet BD, Belardinelli L, Avasarala K, Calhoun WB, Franco EA, Nichols WW, Kerensky RA, and

Hill JA. Differential antagonism of cardiac actions of adenosine by theophylline. Cardiovasc Res 32:839-845, 1996.

93. Belardinelli L, Shryock JC, Ruble J, Monopoli A, Dionisotti S, Ongini E, Dennis DM, Baker, SP.

Binding of the novel nonxanthine A2A adenosine receptor antagonist [3H] SCH58261 to coronary artery membranes. Circ Res 79: 1153-1160, 1996.

94. Song Y, Srinivas M, and Belardinelli L. Nonspecific inhibition of adenosine-activated K+ current by

glibenclamide in guinea pig atrial myocytes. Am J Physiol 271(Heart Circ. Physiol. 40): H2430-H2437, 1996.

95. Bertolet BD, Belardinelli L, Franco EA, Nichols WW, Kerensky RA, and Hill JA. Selective attenuation

by N0861 (N6-endonorboran-2-yl-9-methyladenine) of cardiac A1 adenosine receptor mediated effects in humans. Circulation 93:1871-1876, 1996.

96. Scammels PJ, Baker SP, Belardinelli L, Olsson RA, Russell RA, and Wright D.M.J. The synthesis

of the novel adenosine agonists, exo- and endo- N6- (5,6-eopxynorborn-2-yl) adenosine. Tetrahedron 52:4735-4744, 1996.

97. Kollias-Baker CA, Ruble J, Jacobson M, Harrison JK, Ozeck M, Shryock JC, and Belardinelli L.

Agonist-independent effect of an allosteric enhancer of the A1 adenosine receptor in CHO cells stably expressing the recombinant Human A1 Receptor. JPET 281:761-768, 1997.

98. Shryock JC and Belardinelli L. Adenosine and adenosine receptors in the cardiovascular system:

biochemistry, physiology, and pharmacology. Am J Cardiol 79(12A):2-10, 1997. 99. Pfister JR, Belardinelli L, Lee G, Lum RT, Milner P, Stanley WC, Linden J, Baker SP and Schreiner

G. Synthesis and biological evaluation of the enantiomers of the potent and selective A1-adenosine antagonist 1,3-dipropyl-8-[2-(5,6-epoxynorbonyl)]-xanthine. J.Med.Chem. 40:1773-1778, 1997.

100. Bertolet BD, Hill JA, Kerensky RA, and Belardinelli L. Myocardial infarction related atrial fibrillation:

role of endogenous adenosine. Heart 78:88-90, 1997. 101. Zhang, J, Belardinelli L, Jacobson KA, Otero DH, and Baker SP. Persistent activation by and

receptor reserve for an irreversible A1-adenosine receptor agonist in DDT1MF-2 cells and in guinea pig heart. Mol Pharmacol 52:491-498, 1997.


9

102. Srinivas M, Shryock JC, Dennis DM, Baker SP, and Belardinelli L. Differential A1 adenosine

receptor reserve for two actions of adenosine on guinea pig atrial myocytes. Mol Pharmacol 52:683-691, 1997.

103. Curtis AB, Belardinelli L, Woodard DA, Brown CS, and Conti JB. Induction of AV nodal reentrant

tachycardia with adenosine: Differential effect of adenosine on fast and slow AV nodal pathways. J Am Coll Cardiol 30:1778-1784, 1997.

104. Lee C-S, Lai W-T, Wu J-C, Sheu S-H, Wu, S-N, Belardinelli L. Differential effects of adenosine on

antegrade and retrograde fast pathway conduction in atrioventricular nodal reentry. Am Heart J 134:799-806, 1997.

105. Morey TE, Belardinelli L, Dennis DM. Validation of Furchgott's method to determine agonist-

dependent A1-adenosine receptor reserve in guinea-pig atrium. Brit. J. Pharmacol 123:1425-1433, 1998.

106. Shryock JC, Ozeck MJ, Belardinelli L. Inverse agonists and neutral antagonists of recombinant

human A1 adenosine receptors stably expressed in Chinese hamster ovary cells. Molecular Pharm 53:886-893, 1998.

107. Song Y, Shryock JC, Belardinelli L. Potentiating effect of acetylcholine on stimulation by

isoproterenol of L-type Ca2+ current and arrhythmogenic triggered activity in guinea pig ventricular myocytes. J Cardiovasc Electrophysiol 9:718-726, 1998.

108. Shryock JC, Snowdy S, Baraldi PG, Cacciari B, Spalluto G, Monopoli A, Ongini E, Baker SP,

Belardinelli L. A2A-adenosine receptor reserve for coronary vasodilation. Circ 98:711-718, 1998. 109. Martynyuk AE, Morey TE, Belardinelli L, Dennis DM. Hyperkalemia enhances the effect of

adenosine on IKAdo in rabbit isolated AV nodal myocytes and on AV nodal conduction in guinea pig isolated heart. Circulation 99:312-318, 1998.

110. Srinivas M, Song Y, Shryock JC, Belardinelli L. Cardiac electrophysiological actions of adenosine. Drug Dev. Res. 45:420-426. 1998. 111. Wolff AA, Skettino SL, Beckman E, Belardinelli L. Renal effects of BG 9719, a specific A1 adenosine receptor antagonist, in congestive heart failure. Drug Dev. Res. 45:166-171, 1998. 112. Snowdy S, Liang H-X, Blackburn B, Lum R, Nelson M, Wang L, Pfister J, Sharma B, Wolff, Belardinelli L. A comparison of an A1 adenosine receptor agonist (CVT-510) and diltiazem for slowing of AV nodal conduction. Brit. J. Pharmacol. 126:137-146, 1999. 113. Wilcox CS, Welch WF, Schreiner GF, Belardinelli L. Natriuretic and diuretic actions of a highly selective adenosine A1 receptor antagonist. J Am Soc Nephrol 10:714-720, 1999. 114. Varani K, Portaluppi F, Merighi S, Ongini E, Belardinelli L., Borea PA. Caffeine alters A2A

adenosine receptors and their function in human platelets. Circulation 99:2499-2502, 1999. 115. Grant MB, Tarnuzzer RW, Caballero S, Ozeck MJ, Davis MI, Spoerri PE, Feoktistov I, Biaggioni I, Shryock JC, Belardinelli L. Adenosine receptor activation induces vascular Endothelial growth factor in human retinal endothelial cells. Circ Res. 85:699-706, 1999. 116. Hein TW, Belardinelli L, Kuo L. Adenosine A2A receptors mediate coronary microvascular dilation to adenosine: role of nitric oxide and ATP-sensitive potassium channels. JPET 291: 655-664, 1999. 117. Harrison JK, Jiang Y, Wees EA, Salafranca MN, Liang HX, Feng L, Belardinelli L. Inflammatory agents regulate in vivo expression of fractalkine in endothelial cells of the rat heart. J Leukoc. Biol. 66:937-944, 1999.


10

118. Varani K, Portaluppi F, Gessi S, Merighi S, Ongini E, Belardinelli L, Borea A. Dose and Time Effects of Caffeine Intake on Human Platelet Adenosine A2A Receptors. Circ 102:285-289, 2000. 119. Erga KS, Seubert CN, Liang H-X, Wu L, Shryock JC, Belardinelli L. Role of A2A-Adenosine Receptor Activation for ATP-Mediated Coronary Vasodilation in Guinea-Pig Isolated Heart. Brit J Pharmcol 130:1065-1075, 2000. 120. Baker SP, Scammells PJ, Belardinelli L. Differential A1-Adenosine Receptor Reserve for Inhibition of Cyclic AMP Accumulation and G-protein Activation in DDT1, MF-2 Cells. Brit J Pharmcol 130:1156-1164, 2000. 121. Wu L, Belardinelli L. Zablocki J. Palle V. Shryock J. A partial agonist of the A1-adenosine receptor

selectively slows AV conduction in guinea pig hearts. Am J. Physiol. 280:H334-H343, 2001. 122. Gao Z, Rosete J, Kohler, G, Huang B, Blackburn B, Belardinelli L. Negative Chronotropic Effect of

CVT-510 in Anesthetized and Awake Rats. Drug Development Research 52:424-430 2001. 123. Song Y, Shryock JC, Knot HJ, Belardinelli L. Selective attenuation by adenosine of arrhythmogenic

action of isoproterenol on ventricular myocytes. Am J. Physiol. 280:H2789-H2795, 2001. 124. Gao Z, Li Z, Baker SP, Lasley RD, Meyer S, Elzein El, Palle V, Zablocki JA, Blackburn B, Belardinelli

L. Novel Short-Acting A2A Adenosine Receptor Agonists for Coronary Vasodilation: Inverse Relationship between Affinity and Duration of Action of A2A Agonists. J. Pharm. And Exp. Ther 298: 209-218, 2001.

125. Belardinelli R, Belardinelli L, Shryock JC. Effects of dipyridamole on coronary collateralization and

myocardial perfusion of patients with ischemic cardiomyopathy. Eur Heart J. 22:1205-1213, 2001. 126. Grant MB, Davis MI, Caballero S, Feoktistov I, Biaggioni I, Belardinelli L. Proliferation, migration,

and ERK activation in human retinal endothelial cells through A2B adenosine receptor stimulation. Invest Ophthalmol. Vis. Sci. 42:2068-2073, 2001.

127. Feoktistov I, Garland EM, Goldstein AE, Zeng D, Belardinelli L, Wells, J.N., Biaggioni, I. Inhibition of

human mast cell activation with the novel selective adenosine A2B receptor antagonist 3-isobutyl-8-pyrrolidinoxanthine (IPDX). Biochem Pharm 62:1163-1173, 2001.

128. Lerman BB, Ellenbogen KA, Kadish A, Platia E, Stein, KM, Markowitz SM, Mittal S, Slotwiner

DJ, Scheine M, Iwai S, Belardinelli L, Jerling M, Wolff AA. Electrophysiologic effects of a novel selective adenosine A1 agonist (CVT-510) on atrioventricular nodal conduction in humans. J Cardiovasc Pharmacol Ther. 6(3):237-45, 2001.

129. Mino RP, Spoerri P, Caballero S, Player D, Belardinelli L, Biaggioni I. Adenosine Receptor Antagonists and Retinal Neovascularization in Vivo. Investigative Ophthalmology & Visual Science, 42(13):3320-3324, 2001.

130. Zablocki J, Palle V, Blackburn B, Elzein E, Nudelman G,Gothe S, Gao Z, Li Z, Meyer S, Belardinelli

L. 2-substituted PI system derivatives of adenosine that are coronary vasodilators acting via the A2A adenosine receptor. Nucleosides, Nucleotides & Nucleic Acids. 20(4-7):343-360, 2001.

131. Song Y, Wu L, Shryock J, Belardinelli L. Selective Attenuation of Isoproterenol-Stimulated

Arrhythmic Activity by a Partial Agonist of Adenosine A1 Receptor. Circulation 105:118-123, 2002. 132. Xu J, Ren JF, Mugelli A, Belardinelli L, Keith JC, Pelleg A. Age-Dependent Atrial Remodeling

Induced by Recombinant Human Interleukin-11: Implications for Atrial Flutter/Fibrillation. J. Cardiovasc. Pharma. 39:435-440, 2002.


11

133. Feoktistov I, Goldstein AE, Ryzhov S, Zeng D, Belardinelli L, Voyno-Yasenetshaya T, Biaggioni I. Differential Expression of Adenosine Receptors in Human Endothelial Cells – role of A2B Receptors in Angiogenic Factor Regulation. Circulation Research. 90:531-538, 2002.

134. Liang HX, Belardinelli L, Ozeck MJ, Shryock JC. Tonic Activity of the Rat Adipocyte A1-Adenosine

Receptor. Brit J. Pharmacology. 135:1457-1466, 2002. 135. Sartiani L, De Paoli P, Lonardo G, Pino R, Conti AA, Cerbai E, Pelleg A, Belardinelli L, Mugelli A.

Does Recombinant Human Interleukin-11 Exert Direct Electrophysiologic Effects on Single Human Atrial Myocytes? J. Cardiovasc Pharma. 39:425-434, 2002.

136. Martynyuk AE, Seubert CN, Zima A, Morey TE, Belardinelli L, Lin G, Cucchiara RF, Dennis DM.

Contribution of IK,Ado to the Negative Dromotropic Effect of Adenosine. Basic Res Cardiol 97:286-294, 2002.

137. Martynyuk AE, Zima A, Seubert CN, Morey TE, Belardinelli L, Dennis DM. Potentiation of the

Negative Dromotropic Effect of Adenosine by Rapid Heart Rates: Possible Ionic Mechanisms. Basic Res Cardiol 97:295-304, 2002.

138. Dhalla AK, Shryock JC, Shreeniwas R, Belardinelli L. Pharmacology and Therapeutic Applications of A1 Adenosine Receptor Ligands. Current Topics in Medicinal Chemistry. 3:363-385, 2003.

139. Trochu JN, Zhao, G, Post H, Xu X, Belardinelli L, Belloni FL, Hintze TH. Selective A2A Adenosine Receptor Agonist as a Coronary Vasodilator in Conscious Dogs: Potential for Use in Myocardial Perfusion Imaging. Journal of Cardiovascular Pharmacology, 41:132-139, 2003.

140. Fraser H, Gao Z, Ozeck MJ, Belardinelli L. N-[3-®-Tetrahydrofuranyl]-6-aminopurine Riboside, an A1

Adenosine Receptor Agonist, Antagonizes Catecholamine-Induced Lipolysis without Cardiovascular Effects in Awake Rats. The Journal of Pharmacology and Experimental Therapeutics, 305:225-231, 2003.

141. Zeng D, Maa T, Wang U, Feoktistov I, Biaggioni I, Belardinelli, L. Expression and Function of A2B

Adenosine Receptors in the U87MG Tumor Cells. Drug Development Research 58:405-411, 2003.

142. Zhao G, Linke A, Xu X, Ochoa M, Belloni F, Belardinelli L, Hintze TH. Comparative Profile of Vasodilation by CVT-3146, a Novel A2A Receptor Agonist, and Adenosine in Conscious Dogs. J Pharmacol Exp Ther. Oct;307(1):182-9, 2003.

143. Afzal A, Shaw LC, Caballero S, Spoerri PE, Lewin AS, Zeng D, Belardinelli L, Grant MB. Reduction in Pre-retinal Neovascularization by Ribozymes that Cleave the A2B receptor mRNA. Circ. Res. 93:500-506, 2003.

144. Belardinelli L, Antzelevitch C, Vos, M. Assessing Predictors of Drug-Induced Torsade de Pointes. Trends Pharmacol. Sci. 24:609-660, 2003.

145. Prystowski EN, Niazi I, Curtis AB, Wilbur DJ, Bahnson T, Ellenbogen K, Dhalla A, Bloomfield BM, Gold M, Kadish A, Fogel RI, Gonzalez MD, Belardinelli L, Shreeniwas R, Wolff A. Termination of Paroxysmal Supraventricular Tachycardia by Tecadenoson (CVT-510), A Novel A1-Adenosine Receptor Agonist. J Am Coll Cardiol. 42:1098-1102, 2003.

146. Di-Diego JM, Belardinelli L, Antzelevitch C. Cisapride-induced Transmural Dispersion of Repolarization and Torsade de Pointes in the Canine Left Ventricular Wedge Preparation During Epicardial Stimulation. Circulation. 26:108(8):1027-33, 2003.

147. Zhong H, Belardinelli L, Maa T, Feokistov I, Biaggioni I, Zeng D. A2B Adenosine Receptors Increase Cytokine Release by Bronchial Smooth Muscle Cells. A. J. Respir. Cell Mol. Biol. 30:118-125, 2004.

148. Zablocki J, Wu L, Shryock J, Belardinelli L. Partial A1 Adenosine Receptor Agonists from a Molecular Perspective and Their Potential Use as Chronic Ventricular Rate Control Agents During Atrial Fibrillation (AF). Current Topics in Medical Chemistry 4:839-854, 2004.


12

149. Wu L, Shryock JC, Song Y, Li Y, Antzelevitch C, Belardinelli L. Antiarrhythmic Effects of Ranolazine in a Guinea Pig in vitro Model of Long-QT Syndrome. Journal of Pharmacology and Experimental Therapeutics 310:595-605, 2004.

150. Schram G, Zhang L, Derakhchan K, Ehrlich JR, Belardinelli L, Nattel S. Ranolazine: Ion channel blocking actions and in vivo electrophysiological effects. British Journal of Pharmacology 142:1300-1308, 2004.

151. Song Y, Shryock JC, Wu L, Belardinelli L. Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes. J Cardiovasc Pharmacol 11:192-199, 2004.

152. Antzelevitch C, Belardinelli L, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM, Cordeiro JM and Thomas G. Electrophysiologic effects of ranolazine. A novel anti-anginal agent with antiarrhythmic properties. Circulation 110:904-910, 2004.

153. Antzelevitch C, Belardinelli L, Wu L, Fraser H, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM, Cordeiro JM, Goodrow RJ, Scornik F, Perez G. Electrophysiologic Properties of Ranolazine: A Novel Anti-Anginal Agent. The Journal of Cardiovascular Pharmacol Therapeut 9 (Supplement I):S65-S83, 2004.

154. Shryock JC, Song Y, Wu L, Fraser H, Belardinelli L. A mechanistic approach to assess the proarrhythmic risk of QT-prolonging drugs in preclinical pharmacologic studies. The Journal of Electrocardiology (Supplement Vol. 37): 34-39, 2004.

155. Zhong H. Belardinelli L. Maa T. Zeng D. 2004. Synergy between A2B Adenosine Receptors and Hypoxia in Activating Human Lung Fibroblasts. Am J Respir Cell Mol Biol. 32:2-8, 2005.

156. Belardinelli L, Antzelevitch C, Fraser H, 2004. Inhibition of late (sustained/persistent) sodium

current: a potential drug target to reduce intracellular sodium-dependent effects on cardiomyocyte function. European Heart Journal Supplements (Supplement 1) 6:13-17, 2004.

157. Ellenbogen KA, O’Neill G, Prystowsky EN, Camm JA, Meng L, Lieu HD, Jerling M, Shreeniwas R,

Belardinelli L, Wolff AA, for the TEMPEST Study Group*. Trial to Evaluate the Management of paroxysmal Supraventricular Tachycardia during an Electrophysiology Study with Tecadenoson. Circulation. 111(24):3202-3208, 2005.

158. Fraser H, Ivey PE, Kati J, Koltun DO, Xia J, Belardinelli L. Ranolazine Reduces ATX-II-Induced

Contracture in Rat Left Atria. 25th European Section Meeting - International Society for Heart Research. 27-32, 2005.

159. Belardinelli L, Shryock, Wu L, Song Y. Use of preclinical assays to predict risk of drug-induced

torsades de pointes. Heart Rhythm 2 (Suppl.): S16-S22, 2005. 160. Wu L, Shryock JC, Song Y, Belardinelli L. An increase in late sodium current potentiates the

proarrhythmic activities of low-risk QT-Prolonging drugs in female rabbit hearts. J Pharmacol Exp Ther 316:718-726, 2006.

161. Dhalla A, Wong M, Wang W, Biaggioni I, Belardinelli L. Tachycardia Caused by A2A Adenosine

Receptor Agonists is Mediated by Direct Sympathoexcitation in Awake Rats. JPET 316:695-702, 2006.

162. Belardinelli L, Shryock JC, Fraser H. The mechanism of ranolazine action to reduce ischemia-

induced diastolic dysfunction. Eur Heart 8 (Suppl. A):A10-A13, 2006. 163. Undrovinas A, Belardinelli L, Undrovinas N, Sabbah H. Ranolazine improves abnormal

repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current. J. Cardiovasc Electrophysiol. 17(Suppl. 1):S169-S177, 2006.


13

164. Antzelevitch C, Belardinelli L. The role of sodium channel current in modulating transmural dispersion of repolarization and arrhythmogenesis. J Cardiovasc Electrophysiol. 17 (Suppl 1):S79-S85, 2006.

165. Song Y, Shryock JC, Wagner S, Maier LS, Belardinelli L. Blocking late sodium current reduced

hydrogen peroxide-induced arrhythmogenic activity and contractile dysfunction. J Pharmacol Exp Ther 318: 214-222, 2006.

166. Belardinelli L, Shryock JC, Fraser H. Inhibition of the late sodium current as a potential

cardioprotective principle: effects of the late sodium current inhibitor, ranolazine. Heart 92 (Suppl. IV):IV6-IV14, 2006.

167. Sun C, Zhong H, Mohsenin A, Morschi E, Chunn J, Molina J, Belardinelli L, Zeng D, Blackburn M.

Role of A2B Adenosine Receptor Signaling in Adenosine-Dependent Pulmonary Inflammation and Injury. J. Clin. Invest. 116: 2173-2182, 2006.

168. Zhao G, Messina E, Xu X, Ochoa M, Serpillon S, Shryock J, Belardinelli L, Hintze TH. Ranolazine, a

novel anti-anginal agent, does not alter isorbide dinitrate- or sildenafil-induced changes in blood pressure in conscious dogs. European Journal of Physiology 541:171-176, 2006.

169. Fatholahi Marjan, Xiang Yiwen, Wu Yuzhi, Li Yuan, Wu Lin, Dhalla Arvinder K., Belardinelli Luiz,

Shryock John C. A Novel Partial Agonist of the A1-Adenosine Receptor and Evidence of Receptor Homogeneity in Adipocytes. The Journal of Pharmacology and Experimental Therapeutics. 317:676-684, 2006.

170. Fraser H, Belardinelli L, Wang L, Light PE, McVeigh JJ, Clanachan AS. Ranolazine Decreases

Diastolic Calcium Accumulation Caused by ATX-II or Ischemia in Rat Hearts. Journal of Molecular and Cellular Cardiology. 41:1031-1038, 2006.

171. Zhong H, Wu Yuzhi, Belardinelli L, and Zeng D. A2B Adenosine Receptors Induce IL-19 from

Bronchial Epithelial Cells, Resulting in TNF-α Increase. American Journal of Respiratory Cell and Molecular Biology. 35:587-592, 2006.

172. Gordi T, Frohna P, Sun HL, Wolff A, Belardinelli L, Lieu H. A Population

Pharmacokinetic/Pharmacodynamic Analysis of Regadenoson, an Adenosine A2A-receptor Agonist, in Healthy Male Volunteers. Clin Pharmacokinet. 45(12):1201-1212, 2006.

173. Imai M, Rastogi S, Sharma N, Chandler MP, Sharov VG, Blackburn B, Belardinelli L, Stanley WC,

Sabbah HN. CVT-4325 Inhibits Myocardial Fatty Acid Uptake and Improves Left Ventricular Systolic Function Without Increasing Myocardial Oxygen Consumption in Dogs with Chronic Heart Failure. Cardiovasc Drugs Ther. 21(1):9-15, 2007.

174. Mustafa SJ, Nadeem A, Fan M, Zhong H, Belardinelli L, and Zeng Dewan. Effect of a Specific and

Selective A2B Adenosine Receptor Antagonist on Adenosine Agonist AMP and Allergen-Induced Airway Responsiveness and Cellular Influx in a Mouse Model of Asthma. The Journal of Pharmacology and Experimental Therapeutics. 320:1246-1251, 2007.

175. Wang P, Fraser H, Lloyd SG, McVeigh JJ, Belardinelli L, Chatham JC. A Comparison Between

Ranolazine and CVT-4325, a Novel Inhibitor of Fatty Acid Oxidation, on Cardiac Metabolism and Left Ventricular Function in Rat Isolated Perfused Heart During Ischemia and Reperfusion. J Pharmacol Exp Ther. 321(1):213-220, 2007.

176. Dhalla AK, Santikul M, Smith M, Wong MY, Shryock JC, Belardinelli L. Antilipolytic Activity of a

Partial A1 Adenosine Receptor Devoid of Cardiovascular Effects: Comparison With Nicotinic Acid. J Pharmacol Exp Ther. 321(1):327-333, 2007.

177. Dhalla AK, Wong MY, Voshol PJ, Belardinelli L, Reaven GM. A1 Adenosine Receptor Partial Agonist

Lowers Plasma FFA and Improves Insulin Resistance Induced by High-Fat Diet in rodents. Am J Physiol Endocrinol Metab. 292(5):E1358-E1363, 2007.


14

178. Yang M, Soohoo D, Soelaiman S, Kalla R, Zablocki J, Chu N, Leung K, Yao L, Diamond I,

Belardinelli L, Shryock JC. Characterization of the potency, selectivity, and Pharmacokinetic Profile for Six Adenosine A2A Receptor Antagonists. Naunyn Schmiedebergs Arch Pharmacol. 375(2):133-144, 2007.

179. Sicouri S, Timothy KW, Zygmunt AC, Glass A, Goodrow RJ, Belardinelli L, Antzelevitch C. Cellular

Basis for the Electrocardiographic and Arrhythmic Manifestations of Timothy syndrome: Effects of Ranolazine. Heart Rhythm. 4(5):638-647, 2007.

180. Zhao G, Messina E, Xu X, Ochoa M, Sun HL, Leung K, Shryock J, Belardinelli L, Hintze TH. Caffeine Attenuates the Duration of Coronary Vasodilation and Changes in Hemodynamics Induced by Regadenoson (CVT-3146), a Novel Adenosine A2A Receptor Agonist. J Cardiovasc Pharmacol. 49(6):369-375, 2007. 181. Lieu HD, Shryock JC, von Mering GO, Gordi T, Blackburn B, Olmsted AW, Belardinelli L, Kerensky

RA. Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans. J Nucl Cardiol. 14(4):514-20, 2007.

182. Burashnikov A, Di Diego JM, Zygmunt AC, Belardinelli L, Antzelevitch C. Atrium-Selective Sodium

Channel Block as a Strategy for Suppression of Atrial Fibrillation. Differences in Sodium Channel Inactivation Between Atria and Ventricles and the Role of Ranolazine. Circulation. 116:1449-1457, 2007.

183. Scirica BM, Morrow DA, Hod H, Murphy SA, Belardinelli L, Hedgepeth CM, Molhoek P, Verheugt

FW, Gersh BJ, McCabe CH, Braunwald E. Effect of Ranolazine, an Antianginal Agent With Novel Electrophysiological Properties, on the Incidence of Arrhythmias in Patients With Non ST-Segment Elevation Acute Coronary Syndrome: Results From the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) Randomized Controlled Trial. Circulation. 116:1647-1652, 2007.

184. Iskandrian AE, Bateman TM, Belardinelli L, Blackburn B, Cerqueira MD, Hendel RC, Lieu H,

Mahmarian JJ, Olmsted A, Underwood SR, Vitola J, Wang W; ADVANCE MPI Investigators. Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol. 14(5):645-58, 2007.

185. Wu L, Rajamani S, Shryock JC, Li H, Ruskin J, Antzelevitch C, Belardinelli L. Augmentation of Late

Sodium Current Unmasks the Proarrhythmic Effects of Amiodarone. Cardiovasc Res. 77(3):481-8, 2008.

186. Shryock JC, Belardinelli L. Inhibition of late sodium current to reduce electrical and mechanical

dysfunction of ischaemic myocardium. Br J Pharmacol. 153(6):1128-32, 2008. 187. Song Y, Shryock JC, Belardinelli L. An increase of late sodium current induces delayed

afterdepolarizations and sustained triggered activity in atrial myocytes. Am J Physiol Heart Circ Physiol. 294(5):H2031-9, 2008.

188. Burashnikov A, DI Diego JM, Zygmunt AC, Belardinelli L, Antzelevitch C. Atrial-selective sodium

channel block as a strategy for suppression of atrial fibrillation. Ann N Y Acad Sci. 1123:105-12, 2008.

189. Wang WQ, Robertson C, Dhalla AK, Belardinelli L. Anti-Torsadogenic Effects of Ranolazine in

Anesthetized Rabbits. J Pharmacol Exp Ther. 325(3):875-81, 2008. 190. Sossalla S, Wagner S, Rasenack EC, Ruff H, Weber SL, Schöndube FA, Tirilomis T, Tenderich G,

Hasenfuss G, Belardinelli L, Maier LS. Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts - Role of late sodium current and intracellular ion accumulation. J Mol Cell Cardiol. 45(1):32-43, 2008.


15

191. Kumar K, Nearing BD, Bartoli CR, Kwaku KF, Belardinelli L, Verrier RL. Effect of Ranolazine on Ventricular Vulnerability and Defibrillation Threshold in the Intact Porcine Heart. J Cardiovasc Electrophysiol. 19(10):1073-9, 2008.

192. Hale SL, Shryock JC, Belardinelli L, Sweeney M, Kloner RA. Late sodium current inhibition as a new

cardioprotective approach. J Mol Cell Cardiol. 44(6): 954-67, 2008. 193. Wu L, Belardinelli L, Fraser H. A novel partial fatty acid oxidation inhibitor decreases myocardial

oxygen consumption and improves cardiac efficiency in demand-induced ischemic heart. J Cardiovasc Pharmacol. 51(4):372-9, 2008.

194. Rajamani S, Shryock JC, Belardinelli L. Rapid kinetic interactions of ranolazine with HERG k+

current. J Cardiovasc Pharmacol. 51(6):581-9, 2008. 195. Pelleg A, Belardinelli L. The first second-generation adenosine drug enters the US market.

Purinergic Signal. 4(4):407-8, 2008. 196. Sicouri S, Glass A, Belardinelli L, Antzelevitch C. Antiarrhythmic effects of ranolazine in canine

pulmonary vein sleeve preparations. Heart Rhythm. 5(7):1019-26, 2008. 197. Zaza A, Belardinelli L, Shryock JC. Pathophysiology and pharmacology of the cardiac "late sodium

current" Pharmacol Ther. 119(3):326-39, 2008. 198. Rastogi S, Sharov VG, Mishra S, Gupta RC, Blackburn B, Belardinelli L, Stanley WC, Sabbah HN.

Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure.Am J Physiol Heart Circ Physiol. 295(5):H2149-55, 2008.

199. Zhao G, Serpllion S, Shryock J, Messina E, Xu X, Ochoa M, Belardinelli L,Hintze TH. Regadenoson,

a novel pharmacologic stress agent for use in myocardial perfusion imaging, does not have a direct effect on the QT interval in conscious dogs. J Cardiovasc Pharmacol. 52(5):467-73, 2008.

200. Rajamani S, Shryock JC, Belardinelli L. Block of tetrodotoxin-sensitive, Na(V)1.7 and tetrodotoxin-

resistant, Na(V)1.8,Na(+) channels by ranolazine. Channels (Austin). 7;2(6), 2008. 201. Wu L, Guo D, Li H, Hackett J, Yan GX, Jiao Z, Antzelevitch C, Shryock JC, Belardinelli L. Role of

late sodium current in modulating the proarrhythmic and antiarrhythmic effects of quinidine. Heart Rhythm. 5(12):1726-34, 2008.

202. Wu J, Cheng L, Lammers. W J, Wu L, Wang X, Shryock JC, Belardinelli L, Lei M. Sinus node

dysfunction in ATX-II-induced in-vitro murine model of long QT3 syndrome and rescue effect of ranolazine. Prog Biophys Mol Biol. 98(2-3):198-207, 2008.

203. Dhalla AK, Santikul M, Chisholm JW, Belardinelli L, Reaven GM. Comparison of the antilipolytic

effects of an A(1) adenosine receptor partial agonist in normal and diabetic rats. Diabetes Obes Metab. 11:95-101, 2009.

204. Shearer J, Severson DL, Su L, Belardinelli L, Dhalla A. Partial a1 adenosine receptor agonist

regulates cardiac substrate utilization in insulin resistant rats in vivo. J Pharmacol Exp Ther. 328(1):306-11, 2009.

205. Hage FG, Heo J, Franks B, Belardinelli L, Blackburn B, Wang W, Iskandrian AE. Differences in heart

rate response to adenosine and regadenoson in patients with and without diabetes mellitus. Am Heart J. 157(4):771-6, 2009.

206. Hwang H, Arcidi J, Hale SL, Simkhovich BZ, Belardinelli L, Dhalla AK, Shryock JC, Kloner RA.

Ranolazine as an adjunct to cardioplegia: a potential new therapeutic application. J Cardiovasc Pharmacol Ther. 14(2):125-33, 2009.


16

207. Sicouri S, Belardinelli L, Carlsson L, Antzelevitch C. Potent antiarrhythmic effects of chronic amiodarone in canine pulmonary vein sleeve preparations. J Cardiovasc Electrophysiol. 2009 Jul;20(7):803-10.

208. Kumar K, Nearing BD, Carvas M, Nascimento BC, Acar M, Belardinelli L, Verrier RL. Ranolazine

Exerts Potent Effects on Atrial Electrical Properties and Abbreviates Atrial Fibrillation Duration in the Intact Porcine Heart. J Cardiovasc Electrophysiol; 20(7): 796-802, 2009.

209. Wu Y, Song Y, Belardinelli L, Shryock J. The late INa Inhibitor Ranolazine Attenuates Effect of

Palmitoyl-L-Carnitine to Increase Late INa and Cause Ventricular Diastolic Dysfunction. J Pharmacol Exp Ther. Aug; 330(2):550-7, 2009.

210. Wu L, Rajamani S, Li H, January CT, Shryock JC, Belardinelli L. Reduction of Repolarization

Reserve Unmasks the Pro-arrhythmic Role of Endogenous Late Sodium Current in the Heart. Am J Physiol Heart Circ Physiol; 297(3):H1048-57, 2009.

211. Rajamani S, El-Bizri N, Shryock J, Makielski J, Belardinelli L. Use-Dependent Block of Cardiac Late

Na+ Current by Ranolazine. Heart Rhythm; 6(11): 1625-1631, 2009. 212. Wasserstrom A, Sharma R, O'Toole M, Zheng J, Kelly J, Shryock J, Belardinelli L, Aistrup G.

Ranolazine Antagonizes the Effects of Anemone Toxin-II on Intracellular Ca Cycling in Rat Isolated Intact Heart. J Pharmacol Exp Ther; 331(2): 382-391, 2009.

213. Hwang H, Arcidi J, Hale SL, Simkhovich BZ, Belardinelli L, Dhalla AK, Shryock JC, Kloner RA.

Ranolazine as a Cardioplegia Additive Improves Recovery of Diastolic Function in Isolated Rat Hearts. Circulation; 120(11):S16-S21, 2009.

214. Song Y, Shryock J, Belardinelli L. A slowly-inactivating sodium current contributes to spontaneous

diastolic depolarization of atrial myocytes. Am J Physiol Heart Circ Physiol; 297(4):H1254-62, 2009. 215. Mekkaoui C, Jadbabaie F, Dione DP, Meoli DF, Purushothaman K, Belardinelli L, Sinusas, AJ.

Effects of Adenosine and a Selective A2A Adenosine Receptor Agonist on Hemodynamic and Thallium-201 and Technetium-99m SestaMIBI Biodistribution and Kinetics. JACC Cardiovasc Imaging; 2(10): 1198-1208, 2009.

216. Zhang T, Yong SL, Damron DS, Drinko JK, Popovic ZB, Shryock J, Belardinelli L, Wang QK. LQTS

Mutation N1325S in Cardiac Sodium Channel Gene SCN5A Causes Cardiomyocyte Apoptosis, Cardiac Fibrosis and Contractile Dysfunction in Mice. Int J Cardiol. 2011 Mar 3;147(2):239-45.

217. Dhalla A, Wang WQ, Dow J, Shryock J, Belardinelli L, Bhandari A, Kloner R. Ranolazine, an

Antianginal Agent, Markedly Reduces Ventricular Arrhythmias Induced by Ischemia and Iscehmia-Reperfusion. Am J Physiol Heart Circ Physiol; 297(5):H1923-9, 2009.

218. Belardinelli L, Shryock J, Dhalla A. Abnormal left ventricular relaxation in patients with long QT

syndrome. Eur Heart J. 30(22): 2813-4, 2009. 219. Venkataraman R, Belardinelli L, Blackburn B, Heo J, Iskandrian AE. A Study of the Effects of

Ranolazine Using Automated Quantitative Analysis of Serial Myocardial Perfusion Images. JACC Cardiovasc Imaging; 2(11): 1301-1309, 2009.

220. Sicouri S, Burashnikov A, Belardinelli L, Antzelevitch C. Synergistic Electrophysiologic and

Antiarrhythmic Effects of the Combination of Ranolazine and Chronic Amiodarone in Canine Atria. Circ Arrhythm Electrophysiol. 3(1): 88-95, 2010.

221. Antoons G, Oros A, Beekman JDM, Engelen MA, Houtman MJ, Belardinelli L, Stengl M, Vos MA.

Late Na+ Current Inhibition by Ranolazine Reduces Torsades de Pointes in the Chronic Atrioventricular Block Dog Model. J Am Coll Cardiol. 55(8): 801-809, 2010.


17

222. Carvas M, Nascimento BC, Acar M, Nearing BD, Belardinelli L, Verrier RL. Intrapericardial Ranolazine Prolongs Atrial Refractory Period and Markedly Reduces Atrial Fibrillation Inducibility in the Intact Porcine Heart. J Cardiovasc Pharmacol. 55(3): 286-91, 2010.

223. Zhou Y, Murthy JN, Zeng D, Belardinelli L, Blackburn MR. Alterations in adenosine metabolism and

signaling in patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. PLoS One. 5(2):e9224, 2010.

224. Guo D, Young LH, Wu Y, Belardinelli L, Kowey PR, Yan GX. Increased Late Sodium Current in Left

Atrial Myocytes of Rabbits with Left Ventricular Hypertrophy: Its Role in the Genesis of Atrial Arrhythmias. Am J Physiol Heart Circ Physiol. 298(5):H1375-81, 2010.

225. Chisholm JW, Goldfine A, Dhalla AK, Braunwald E, Morrow DA, Karwatowska-Prokopczuk E,

Belardinelli L. Effect of Ranolazine on HbA1c and Glucose Levels in Hyperglycemic Patients with Non-ST Elevation Acute Coronary Syndrome. Diabetes Care 33(6):1163-8, 2010.

226. Miyamoto M, Clarke K, Thomas GS, Belardinelli L. An example of the clinical selectivity of

regadenoson for the A2a adenosine receptor. Am Heart Hosp J. 7(2):E118-21, 2009. 227. Sossalla S, Kallmeyer B, Wagner S, Mazur M, Maurer U, Toischer K, Schmitto JD, Seipelt R,

Schondube FA, Hasenfuss G, Belardnelli L, Maier LS. Altered Na+ currents in atrial fibrillation – Effects of ranolazine on arrhythmias and contractility in human atrial myocardium. J Am Coll Cardiol. 55(21):2330-2342, 2010.

228. Undrovinas NA, Maltsev VA, Belardinelli L, Sabbah HN, Undrovinas A. Late Sodium Current

Contributes to Diastolic Cell Ca2+ Accumulation in Chronic Heart Failure. J Physiol Sci. 60(4):245-57, 2010.

229. Burashnikov A, Belardinelli L, Antzelevitch C. Acute Dronedarone is Inferior to Amiodarone in

Terminating and Preventing Atrial Fibrillation in Canine Atria. Heart Rhythm. 7(9):1273-9, 2010. 230. Scirica BM, Braunwald E, Belardinelli L, Hedgepeth C, Spinar J, Wang W, Qin J, Karwatowska-

Prokopczuk E, Verheught FWA, Morrow DA. Relationship Between Nonsustained Ventricular Tachycardia After Non–ST-Elevation Acute Coronary Syndrome and Sudden Cardiac Death. Observations From the Metabolic Efficiency With Ranolazine for Less Ischemia in Non–ST-Elevation Acute Coronary Syndrome–Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) Randomized Controlled Trial. Circulation; 122(5):455-62, 2010.

231. Oros A, Houtman MJ, Neco P, Gomez AM, Rajamani S, Oosterhoff P, Attevelt NJ, Beekman JD, van

der Heyden MA, Ver Donck L, Belardinelli L, Richard S, Antoons G, Vos MA; for the CONTICA investigators. Robust anti-arrhythmic efficacy of verapamil and flunarizine against dofetilide-induced TdP arrhythmias is based upon a shared and a different mode of action. Br J Pharmacol. 161(1):162-175, 2010.

232. Burashnikov A, Sicouri S, Di Diego JM, Belardinelli L, Antzelevitch C. Synergistic Effect of the

Combination of Ranolazine and Dronedarone to Suppress Atrial Fibrillation. J Am Coll Cardiol. 56(15):1216-24, 2010.

233. Nieminen T, Nanbu DY, Datti IP, Vaz GR, Tavares CA, Pegler JR, Nearing BD, Belardinelli L, Verrier

RL. Antifibrillatory Effect of Ranolazine during Severe Coronary Stenosis in the Intact Porcine Model. Heart Rhythm 8(4):608-14, 2011.

234. Ning Y, Zhen W, Fu Z, Jiang J, Liu D, Belardinelli L, Dhalla AK. Ranolazine increases β-cell survival

and improves glucose homeostasis in low dose STZ-induced diabetes in mice. J Pharmacol Exp Ther. 337(1):50-8, 2011.

235. Wagner S, Ruff HM, Weber SL, Bellmann S, Sowa T, Schulte T, Grandi E, Bers DM, Backs J,

Belardinelli L, Maier LS. Reactive Oxygen Species-Activated Ca/Calmodulin Kinase II{delta} Is


18

Required for Late INa Augmentation Leading to Cellular Na and Ca Overload. Circ Res. 108(5):555-65, 2011.

236. El-Bizri N, Kahlig KM, Shyrock JC, George AL Jr, Belardinelli L, Rajamani S. Ranolazine block of

human NaV 1.4 sodium channels and paramyotonia congenita mutants. Channels (Austin). 5(2), 2011.

237. Hoyer K, Song Y, Wang D, Phan D, Balschi J, Ingwall JS, Belardinelli L, Shryock JC. Reducing the

late sodium current improves cardiac function during sodium pump inhibition by ouabain. J Pharmacol Exp Ther. 337(2):513-23, 2011.

238. Zhao G, Walsh E, Shryock J, Messina E, Wu Y, Zeng D, Xu X, Ochoa M, Baker S, Hintze T,

Belardinelli L. Anti-Adrenergic and Hemodynamic Effects of Ranolazine in Conscious Dogs. J Cardiovasc Pharmacol. Jun;57(6):639-47,2011.

239. Antzelevitch C, Burashnikov A, Sicouri S, Belardinelli L. Electrophysiological Basis for the

Antiarrhythmic Actions of Ranolazine. Heart Rhythm. 8(8):1281-90, 2011. 240. Venkataraman R, Aljaroudi W, Belardinelli L, Heo J, Iskandrian AE. The effect of ranolazine on the

vasodilator-induced myocardial perfusion abnormality. J Nucl Cardiol. 18(3):456-62, 2011. 241. Wu L, Ma J, Li H, Wang C, Grandi E, Zhang P, Luo A, Bers DM, Shryock JC, Belardinelli L. Late

sodium current contributes to the reverse rate-dependent effect of IKr inhibition on ventricular repolarization. Circulation. 123(16):1713-20, 2011.

242. Jacobshagen C, Belardinelli L, Hasenfuss G, Maier LS. Ranolazine for the treatment of patients with

diastolic heart failure: Background, aims, and design of the RALI-DHF study. Clin Cardiol. 34(7):426-32, 2011.

243. Yao L, Fan P, Jiang Z, Viatchenko-Karpinski S, Wu Y, Kornyeyev D, Hirakawa R, Budas GR,

Rajamani S, Shryock JC, Belardinelli L. Nav1.5-dependent persistent Na+ influx activates CaMKII in rat ventricular myocytes and N1325S mice. Am J Physiol Cell Physiol. 301(3):C577-86, 2011.

244. Nesterenko VV, Zygmunt AC, Rajamani S, Belardinelli L, Antzelevitch C. Mechanisms of atrial-

selective block of Na+ channels by ranolazine: II. Insights from a mathematical model. Am J Physiol Heart Circ Physiol. 301(4):H1615-24, 2011.

245. Zygmunt AC, Nesterenko VV, Rajamani S, Hu D, Barajas-Martinez H, Belardinelli L, Antzelevitch C.

Mechanisms of atrial-selective block of Na+ channels by ranolazine: I. Experimental analysis of the use-dependent block. Am J Physiol Heart Circ Physiol. 301(4):H1606-14, 2011.

246. Nieminen T, Tavares CA, Pegler JR, Belardinelli L, Verrier RL. Ranolazine injection into coronary or

femoral arteries exerts marked, transient regional vasodilation without systemic hypotension in an intact porcine model. Circ Cardiovasc Interv. 4(5):481-7, 2011.

247. Zhao G, Zhang S, Shryock JC, Xu X, Ochoa M, Hintze TH, Belardinelli L. Selective action of

metoprolol to attenuate regadenoson-induced tachycardia in conscious dogs. J Nucl Cardiol. 9(1):109-17, 2012.

248. Ma J, Luo A, Wu L, Wan W, Zhang P, Ren Z, Zhang S, Qian C, Shryock JC, Belardinelli L.

Calmodulin kinase II and protein kinase C mediate the effect of increased intracellular calcium to augment late sodium current in rabbit ventricular myocytes. Am J Physiol Cell Physiol. 302 (8):C1141-51, 2012.

249. Burashnikov A, Belardinelli L, Antzelevitch C. Atrial-selective sodium channel block strategy to

suppress atrial fibrillation. Ranolazine versus propafenone. J Pharmacol Exp Ther. 340(1):161-8, 2012.


19

250. Liang F, Yang S, Belardinelli L, Shryock J. Ambrisentan and tadalafil synergistically relax endothelin-induced contraction of rat pulmonary arteries. Hypertension. 59:705-711, 2012.

251. Hirakawa R, El-Bizri N, Shryock JC, Belardinelli L, Rajamani S. Block of Na+ currents and

suppression of action potentials in embryonic rat dorsal root ganglion neurons by ranolazine. Neuropharmacology. 62(7):2251-60, 2012.

252. Lovelock JD, Monasky MM, Jeong EM, Lardin HA, Liu H, Patel BG, Taglieri DM, Gu L, Kumar

P, Pokhrel N, Zeng D, Belardinelli L, Sorescu D, Solaro RJ, Dudley SC Jr. Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity. Circ Res. 110(6):841-50, 2012.

253. Trenor B, Cardona K, Gomez JF, Rajamani S, Ferrero JM Jr, Belardinelli L, Saiz J.

Simulation and mechanistic investigation of the arrhythmogenic role of the late sodium current inhuman heart failure. PLoS One. 7(3):e32659, 2012.

254. Sicouri S, Blazek J, Belardinelli L, Antzelevitch C.

Electrophysiological Characteristics of Canine Superior Vena Cava Sleeve Preparations. Effect of Ranolazine. Circ Arrhythm Electrophysiol. 5(2):371-9, 2012.

255. Karmouty-Quintana H, Zhong H, Acero L, Weng T, Melicoff E, West JD, Hemnes A, Grenz A,

Eltzschig HK, Blackwell TS, Xia Y, Johnston RA, Zeng D, Belardinelli L, Blackburn MR. The A2B adenosine receptor modulates pulmonary hypertension associated with interstitial lung disease. FASEB J. 26(6):2546-57, 2012.

256. Yang M, Chu R, Chisholm JW, Doege H, Belardinelli L, Dhalla AK. Adenosine A(1) receptors do not

play a major role in the regulation of lipogenic gene expression in hepatocytes. Eur J Pharmacol. 15; 683(1-3): 332-9, 2012.

257. Gerczuk PZ, Breckenridge DG, Liles JT, Budas GR, Shryock JC, Belardinelli L, Kloner RA, Dai W.

An apoptosis signal-regulating kinase 1 inhibitor reduces cardiomyocyte apoptosis and infarct size in a rat ischemia-reperfusion model. J Cardiovasc Pharmacol. 60(3):276-82, 2012.

258. Venkataraman R, Chen J, Garcia EV, Belardinelli L, Hage FG, Heo J, Iskandrian AE. Effect of

Ranolazine on Left Ventricular Dyssynchrony in Patients With Coronary Artery Disease. Am J Cardiol. 110(10):1440-5, 2012.

259. Toldo S, Zhong H, Mezzaroma E, Van Tassell BW, Kannan H, Zeng D, Belardinelli L, Voelkel NF, Abbate A. GS-6201, a selective blocker of the A2B adenosine receptor, attenuates cardiac remodeling following acute myocardial infarction in the mouse. J Pharmacol Exp Ther. 343(3):587-95, 2012.

260. Verrier RL, Pagotto VP, Kanas AF, Sobrado MF, Nearing BD, Zeng D, Belardinelli L. Low Doses of

Ranolazine and Dronedarone in Combination Exert Potent Protection against Atrial Fibrillation and Vulnerability to Ventricular Arrhythmias during Acute Myocardial Ischemia. Heart Rhythm. 10(1):121-7, 2013.

261. Belardinelli L, Liu G, Smith-Maxwell C, Wang WQ, El-Bizri N, Hirakawa R, Karpinski S, Kornyeyev D,

Li CH, Hu L, Li XJ, Crumb W, Wu L, Koltun D, Zablocki J, Yao L, Dhalla AK, Rajamani S, Shryock J.

A Novel, Potent, and Selective Inhibitor of Cardiac Late Sodium Current Suppresses Experimental Arrhythmias. J Pharmacol Exp Ther. 344(1):23-32, 2013.

262. Frommeyer G, Kaiser D, Uphaus T, Kaese S, Osada N, Rajamani S, Belardinelli L, Breithardt G,

Eckardt L, Milberg P. Effect of ranolazine on ventricular repolarization in class III antiarrhythmic drug-treated rabbits. Heart Rhythm. (12):2051-8, 2012.


20

263. Frommeyer G, Rajamani S, Grundmann F, Stypmann J, Osada N, Breithardt G, Belardinelli L, Eckardt L, Milberg P. New insights into the beneficial electrophysiologic profile of ranolazine in heart failure: prevention of ventricular fibrillation with increased postrepolarization refractoriness and without drug-induced proarrhythmia. J Card Fail. (12):939-49, 2012.

264. Verrier RL, Kumar K, Nieminen T, Belardinelli L. Mechanisms of ranolazine's dual protection against

atrial and ventricular fibrillation. Europace. 15(3):317-24, 2013. 265. Karwatowska-Prokopczuk E, Wang W, Cheng ML, Zeng D, Schwartz PJ, Belardinelli L. The risk of

sudden cardiac death in patients with non-ST elevation acute coronary syndrome and prolonged QTc interval: effect of ranolazine. Europace. 15(3):429-36, 2013.

266. Coppini R, Ferrantini C, Yao L, Fan P, Del Lungo M, Stillitano F, Sartiani L, Tosi B, Suffredini S, Tesi

C, Yacoub M, Olivotto I, Belardinelli L, Poggesi C, Cerbai E, Mugelli A. Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy. Circulation. 127(5):575-84, 2013.

267. Milberg P, Frommeyer G, Ghezelbash S, Rajamani S, Osada N, Razvan R, Belardinelli L, Breithardt

G, Eckardt L. Sodium channel block by ranolazine in an experimental model of stretch-related atrial fibrillation: prolongation of interatrial conduction time and increase in post-repolarization refractoriness. Europace. 15(5):761-9, 2013.

268. Staehr PM, Dhalla AK, Zack J, Wang X, Ho YL, Bingham J, Belardinelli L. Reduction of Free Fatty

Acids, Safety, and Pharmacokinetics of Oral GS-9667, an A(1) Adenosine Receptor Partial Agonist. J Clin Pharmacol. 53(4):385-92, 2013.

269. Kosiborod M, Arnold S, Spertus J, McGuire D, Li Y, Yue P, Ben-Yehuda O, Katz A, Jones P,

Olmsted A, Belardinelli L, Chaitman B. Evaluation of Ranolazine in Patients with Type 2 Diabetes Mellitus and Chronic Stable Angina. Results from the TERISA randomized clinical trial. J Am Coll Cardiol. 61(20):2038-45, 2013.

270. Sicouri S, Belardinelli L, Antzelevitch C. Antiarrhythmic Effects of the Highly-Selective Late Sodium

Channel Current Blocker GS-458967. Heart Rhythm. 10(7):1036-43, 2013. 271. Toischer K, Hartmann N, Wagner S, Fischer TH, Herting J, Danner BC, Sag CM, Hund TJ, Mohler

PJ, Belardinelli L, Hasenfuss G, Maier LS, Sossalla S. Role of late sodium current as a potential arrhythmogenic mechanism in the progression of pressure-induced heart disease. J Mol Cell Cardiol. 61:111-22, 2013.

272. Sobrado LF, Varone BB, Machado AD, Nearing BD, Zeng D, Belardinelli L, Verrier RL.

Dronedarone's Inhibition of If Current Is the Primary Mechanism Responsible for Its Bradycardic Effect. J Cardiovasc Electrophysiol. 24(8):914-8, 2013.

273. Trenor B, Gomis-Tena J, Cardona K, Romero L, Rajamani S, Belardinelli L, Giles WR, Saiz J. In

silico assessment of drug safety in human heart applied to late sodium current blockers. Channels (Austin). May 21;7(5), 2013 [Epub ahead of print].

274. Shryock JC, Song Y, Rajamani S, Antzelevitch C, Belardinelli L. The arrhythmogenic consequences

of increasing late INa in the cardiomyocyte. Cardiovasc Res. Sep 1;99(4):600-11, 2013. 275. Karmouty-Quintana H, Weng T, Garcia-Morales LJ, Chen NY, Pedroza M, Zhong H, Molina JG,

Bunge R, Bruckner BA, Xia Y, Johnston RA, Loebe M, Zeng D, Seethamraju H, Belardinelli L, Blackburn MR.Adenosine A2B receptor and hyaluronan modulate pulmonary hypertension associated with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. Dec;49(6):1038-47, 2013.

276. Aistrup GL, Gupta DK, Kelly JE, O'Toole MJ, Nahhas AF, Chirayil N, Misener S, Beussink L, Singh

N, Ng J, Reddy M, Mongkolrattanothai T, El-Bizri N, Rajamani S, Shryock JC, Belardinelli L, Shah SJ, Wasserstrom JA. Inhibition of the Late Sodium Current Slows T-tubule Disruption During the


21

Progression of Hypertensive Heart Disease in the Rat. Am J Physiol Heart Circ Physiol. 305(7):H1068-79, 2013.

277. Verrier RL, Sobrado MF, Pagotto VP, Kanas AF, Machado AD, Varone BB, Sobrado LF, Nearing

BD, Zeng D, Belardinelli L. Inhibition of If in the Atrioventricular Node as a Mechanism for Dronedarone's Reduction in Ventricular Rate during Atrial Fibrillation. Heart Rhythm. 2013 Nov;10(11):1692-7.

278. Lars S. Maier, MD; Beth Layug, MD; Ewa Karwatowska-Prokopczuk, MD, PhD; Luiz Belardinelli, MD; Stella Lee, MS; Julia Sander, MS; Christian Lang, MS; Rolf Wachter, MD; Frank Edelmann, MD; Gerd Hasenfuss, MD; Claudius Jacobshagen, MD RAnoLazIne for the Treatment of Diastolic Heart Failure in Patients With Preserved Ejection Fraction: The RALI-DHF Proof-of-Concept Study. JCHF. 1(2):115-122, 2013.

279. Coppini R, Ferrantini C, Del Lungo M, Stillitano F, Sartiani L, Tosi B, Suffredini S, Tesi C, Poggesi C, Cerbai E, Mugelli A, Yao L, Fan P, Belardinelli L, Yacoub M, Olivotto I. Response to letter regarding article, "Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy". Circulation. 3;128(10):e157, 2013.

280. Zhang H, Zhong H, Everett TH 4th, Wilson E, Chang R, Zeng D, Belardinelli L, Olgin JE. Blockade of A2B adenosine receptor reduces left ventricular dysfunction and ventricular arrhythmias one week after myocardial infarction in the rat model. Heart Rhythm. 2013 Oct 9. pii: S1547-5271(13)01160-0.

281. Trenor B, Cardona K, Saiz J, Rajamani S, Belardinelli L, Giles WR. Carbon monoxide effects on human ventricle action potential assessed by mathematical simulations. Front Physiol. 17;4:282, 2013.

282. Kahlig KM, Hirakawa R, Liu L, George AL, Belardinelli L, Rajamani S. Ranolazine Reduces Neuronal Excitability by Interacting with Inactivated States of Brain Sodium Channels. Mol Pharmacol. 85(1):162-74, 2014.

283. Pezhouman A, Madahian S, Stepanyan H, Ghukasyan H, Qu Z, Belardinelli L, Karagueuzian HS. Selective inhibition of late sodium current suppresses ventricular tachycardia and fibrillation in intact rat hearts. Heart Rhythm. 2014 Mar;11(3):492-501.

284. Fernandes S, Hoyer K, Liu G, Wang WQ, Dhalla AK, Belardinelli L, Rajamani S. Selective inhibition of the late sodium current has no adverse effect on electrophysiological or contractile function of the normal heart. J Cardiovasc Pharmacol. 2014 Jan 8. [Epub ahead of print].

285. Burashnikov A, Di Diego JM, Sicouri S, Doss MX, Sachinidis A, Barajas-Martínez H, Hu D, Minoura Y, Sydney Moise N, Kornreich BG, Chi L, Belardinelli L, Antzelevitch C. A temporal window of vulnerability for development of atrial fibrillation with advancing heart failure. Eur J Heart Fail. 16(3):271-80, 2014.

286. Pourrier M, Williams S, McAfee D, Belardinelli L, Fedida D. CrossTalk proposal: The late sodium current is an important player in the development of diastolic heart failure (heart failure with a preserved ejection fraction). J Physiol. 1;592(Pt 3):411-4, 2014.

287. Rebuttal from Marc Pourrier, Sarah Williams, Donald McAfee, Luiz Belardinelli and David Fedida. Pourrier M, Williams S, McAfee D, Belardinelli L, Fedida D. J Physiol. 1;592(Pt 3):419, 2014.


22

288. Maier LS, Layug B, Karwatowska-Prokopczuk E, Belardinelli L, Lee S, Sander J, Lang C, Wachter R, Edelmann F, Hasenfuss G, Jacobshagen C. RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of-concept study. JACC Heart Fail. 1(2):115-22, 2013.

289. Mourouzis I, Mantzouratou P, Galanopoulos G, Kostakou E, Dhalla AK, Belardinelli L, Pantos C. The Beneficial Effects of Ranolazine on Cardiac Function After Myocardial Infarction Are Greater in Diabetic Than in Nondiabetic Rats. J Cardiovasc Pharmacol Ther. 2014 Mar 19. [Epub ahead of print].

290. Ma J, Song Y, Shryock JC, Hu L, Wang W, Yan X, Zhang P, Belardinelli L. Ranolazine Attenuates Hypoxia- and Hydrogen Peroxide-Induced Increases in Sodium Channel Late Openings in Ventricular Myocytes. J Cardiovasc Pharmacol. 2014 Apr 3. [Epub ahead of print].

291. Antzelevitch C, Nesterenko V, Shryock JC, Rajamani S, Song Y, Belardinelli L. The role of late I na in development of cardiac arrhythmias. Handb Exp Pharmacol. 2014, 221:137-68.


23

II. Book Chapters 1. Rubio R., Belardinelli L., Thompson C.I. and Berne R.M.: Cardiac adenosine: Electrophysiological

effects, possible significance in cell function and mechanisms controlling its release. In: Physiological and Regulatory Functions of Adenosine and Adenine Nucleotides, edited by H.P. Baer and G.I. Drummond, New York, Raven Press, pp. 167-182, 1979.

2. Berne R.M., Belardinelli L., Harder D.R., Sperelakis N. and Rubio R.: Response of large and small

coronary arteries to adenosine, nitroglycerin, cardiac glycosides, and calcium antagonists. In: Calcium Antagonisms, edited by A. Fleckenstein and H. Roskamm, New York, Springer Verlag, pp. 208-220, 1980.

3. Sperelakis N., Belardinelli L., and Vogel S.: Electrophysiological aspects during myocardial

ischemia. In: Myocardial metabolism During Ischemia, edited by L. Opie and Y. Ito, Amsterdam, Excerpta Medica, pp. 229-236, 1979.

4. Belardinelli L., West G.A., Crampton R. and Berne R.M.: Chronotropic and dromotropic effects of

adenosine. In: The Regulatory Function of Adenosine, edited by R.M. Berne, T.W. Rall, R. Rubio, The Hague, Martinus Nijhoff Publishers, pp. 377-398, 1983.

5. Berne R.M., Belardinelli L., Winn R.H. and Rubio R.: The adenosine concept in ischemia of heart

and brain. In: Protection of Tissues Against Hypoxia, edited by A. Wauquier, Elsevier Biomedical Press, Amsterdam, pp. 105-114, 1982.

6. Clemo S.H.F. and Belardinelli L.: A comparative study of antagonism by alkylxanthines on the

negative dromotropic effect of adenosine and hypoxia in isolated guinea-pig hearts. In: Anti-asthma Xanthines and Adenosine (Proceedings of a symposium in Copenhagen, February 22-23, 1985). Eds.: K.E. Andersson and C.G.A. Persson. Excerpta Medica, Amsterdam (1985), pp. 417-422.

7. Belardinelli L., West G.A. and Clemo S.H.F.: Regulation of atrioventricular node function by

adenosine. In: Topics and Perspectives in Adenosine Research, Gerlach E. and Becker B.F. (eds), Springer-Verlag, Berlin, pp. 344-355, 1987

8. West G.A., Giles W and Belardinelli L.: The negative chronotropic effect of adenosine in sinus node

cells. In: Topics and Perspectives in Adenosine Research, Gerlach E. and Becker B.F. (eds), Springer-Verlag, Berlin, pp. 337-343, 1987.

9. Belardinelli L.: Modulation of atrioventricular transmission by adenosine. In: Progress in Clinical and

Biological Research, Vol. 230, Pelleg A., Michelson E.L. and Dreifus L.S. (eds), Alan R. Liss, Inc., New York, pp. 109-118, 1987.

10. Lerman B.B. and Belardinelli L.: Effects of adenosine on ventricular tachycardia. In: Progress in

Clinical and Biological Research, Vol. 230, Pelleg A., Michelson E.L. and Dreifus L.S. (eds), Alan R. Liss, Inc., New York, pp. 301-314, 1987.

11. Belardinelli L. and West G.A.: Cardiac electrophysiological effects of adenosine. In: Myocardial

Energy Metabolism, de Jong J.W. (ed), Martinus Nijhoff, Dordrecht, pp. 93-104, 1988. 12. Belardinelli L., Kl"ckner U., and Isenberg G.: Modulation of potassium and calcium currents in atrial

and nodal cells. In: Isolated Adult Cardiomyoctyes, Vol II, H.M. Piper and G. Isenberg (eds), CRC Press, Florida, pp. 155-180, 1989.

13. Belardinelli L. and Pelleg A.: Rationale for use of adenosine in the diagnosis and treatment of

cardiac arrhythmias. In: Purines in Cellular Signaling. Targets for New Drugs, KA Jacobson, KW Daly, and V Manganiello (eds), Springer-Verlag, pp. 95-99, 1990.

14. Belardinelli L., Wu S-N, and Visentin S. Adenosine regulation of cardiac electrical activity. In:

Cardiac Electrophysiology: From Cell to Bedside, D.P Zipes and J. Jalife (eds), W.B. Saunders, Florida, pp. 284-290.


24

15. Belardinelli L. Chronotropic and dromotropic effects of adenosine: physiological consequences. In:

Role of Adenosine and Adenine Nucleotides in the Biological System. S. Imai and M. Nakazawa (eds), Elsevier, pp. 357-368.

16. Song Y, Shryock J, and Belardinelli L. Modulation of cardiomyocyte membrane currents by A1

adenosine receptors. In: Adenosine and Adenine Nucleotides: From Molecular Biology to Integrative Physiology. L. Belardinelli and A. Pelleg (eds), Kluwer Academic Publishers (Boston), pp. 97-102, 1995.

17. Kollias-Baker C, Shryock JC, and Belardinelli L. Myocardial adenosine receptors. In: Adenosine

and Adenine Nucleotides: From Molecular Biology to Integratie Physiology. L. Belardinelli and A. Pelleg (eds), Kluwer Academic Publishers (Boston), pp. 221-228, 1995.

18. Belardinelli L., AB Curtis, and Bertolet B. Cardiac electrophysiology of adenosine: antiarrhythmic

and Proarrhythmic Actions. In: Purinergic Approaches in Experimental Therapeutics. K.A. Jacobson and M.F. Jarvis (eds), Wiley-Liss (New York), pp. 185-202, 1997.

19. Belardinelli L., Song Y., and Shryock JC. Cholinergic and Purinergic Control of Cardiac Electrical

Activity. In: Cardiac Electrophysiology, From Cell to Bedside, Third Edition. DP Zipes and J Jalife (eds), W.B. Saunders Company (Orlando), pp. 294-300, 1998.

20. Lazzara R, Scherlag B, Belardinelli L. Atrio-Ventricular Conduction. P. Spooner and M. Rosen

(eds), Marcel Dekker, Inc. (New York), Chaper 10, pp- 1-29, 1998. 21. Dhalla AK, Chisholm JW, Reaven GM, Belardinelli L. A1 Adenosine Receptor: Role in Diabetes and

Obesity. In: Handb Exp Pharmacol. (193): 271-95, 2009. 22. Zeng D, Karwatowska-Prokopczuk E, Wang W, Belardinelli L. Late Sodium Current as a New

Target of Angina Therapy. In: Cardiologia 2009. Fondazione Centro Cardiologia e Cardiochirurgia (Milano), pp. 292-297, 2009.

III. Books Edited 1. Adenosine and Adenine Nucleotides: From Molecular Biology to Integrative Physiology. Proceedings

of the 5th International Symposium on Adenosine and Adenine Nucleotides, May 9-13, 1994. Kluwer Academic Publishers (Boston), 1995. Belardinelli L. and Pelleg A. (eds.).

2. Molecular Biology Intelligence Unit Series. Effects of Extracellular Adenosine and ATP on

Cardiomyocytes. R.G. Landers Company (Austin), 1998.

curriculum vitae luiz belardinelli, m.d.training.cvrc.virginia.edu/events/474resume.pdf · ed. may...

Documents